Skip to content
Revelation News
Health

FDA Approves First siRNA Therapy for Myasthenia Gravis

Source Summary

The FDA has approved cemdisiran (Livsayis), a subcutaneous siRNA therapy developed by Regeneron, for treating generalized myasthenia gravis in adults with anti-acetylcholine receptor antibody positivity. This marks the first siRNA therapy approved for this autoimmune neuromuscular disorder.

Why it matters

This approval introduces a novel RNA-based mechanism to treat a rare autoimmune disorder previously managed only with conventional immunosuppressive and symptomatic therapies.

Read the Source

NASDAQ:REGNLive chart